Current report
Open the filing on sec.gov
Immunic, Inc. (IMUX)
Nasdaq: IMUX · Pharmaceutical Preparations · New York, US · filing with the SEC since 2004
The companyfiscal 2025, as filed
Revenuen/a
Net income-$97.2M+3.3%
Earnings per share$-0.62+38.0%
Operating cash flow-$85.8M-1.2%
Cash$15.5M-56.6%
Debtn/a
Shareholders’ equity-$6.7M-136.2%
Shares, diluted155.7M+55.4%
Return on equityn/a
The recordfrom its filings
Filings in 202686
Newest filingNov 5 · 8-K
Annual reportFeb 26, 2026
Quarterly reportAug 11, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted4
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$112MCash from operations -$87.7Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Large holder update, amended
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.